Titan Pharmaceuticals Stock

TTNP

US8883147055

Market Closed - Nasdaq 23:00:00 29/09/2026 +03			5-day change	1st Jan Change
0.4630 ^USD	+6.73%		-88.51%	-89.96%

04/10/25	Titan Pharmaceuticals announces closing of merger with Black Titan Corporation	RE
01/10/25	Titan Pharmaceuticals, Inc. Appoints Chay Weei Jye as the Sole Director and Acting Secretary, Effective October 1, 2025	CI

Valuation: Titan Pharmaceuticals

Market Cap	6.13M 5.41M 5.12M 4.64M 8.7M 589M 8.78M 61.17M 23.59M 300M 23.03M 22.52M 965M	P/E 2023	-1.11x	P/E 2024	-0.62x
Enterprise Value	3.3M 2.91M 2.75M 2.5M 4.68M 317M 4.73M 32.93M 12.7M 162M 12.4M 12.13M 519M	EV / Sales 2023	0.11x	EV / Sales 2024	-
Free-Float	-	Yield 2023 *	-	Yield 2024	-

* Estimated data More valuation ratios

Latest news: Titan Pharmaceuticals

04/10/25	Titan Pharmaceuticals announces closing of merger with Black Titan Corporation	RE
01/10/25	Titan Pharmaceuticals, Inc. Appoints Chay Weei Jye as the Sole Director and Acting Secretary, Effective October 1, 2025	CI
01/10/25	Titan Pharmaceuticals, Inc.(NasdaqCM:TTNP) dropped from NASDAQ Composite Index	CI
01/10/25	Ke Sdn. Bhd. completed the acquisition of Titan Pharmaceuticals, Inc. in a reverse merger transaction.	CI
14/08/25	Titan Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
27/06/25	Titan Pharmaceuticals, Inc. announced that it has received $0.6 million in funding from Blue Harbour Asset Management L.L.C	CI
24/06/25	Titan Pharmaceuticals, Inc. announced that it expects to receive $0.6 million in funding from Blue Harbour Asset Management L.L.C	CI
14/05/25	Titan Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
11/04/25	Titan Pharmaceuticals Announces $1 Million Private Placement Of Convertible Preferred Stock	RE
11/04/25	Titan Pharmaceuticals, Inc. announced that it has received $1 million in funding	CI
01/04/25	Titan Pharmaceuticals, Inc. Appoints Gabriel Loh as an Independent Director and Member of the Audit Committee	CI
29/03/25	Titan Pharmaceuticals, Inc. announced that it expects to receive $1 million in funding	CI
20/03/25	Titan Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI

More news

Analysts' recommendations: Titan Pharmaceuticals

26/05/22	Maxim Downgrades Titan Pharmaceuticals to Hold From Buy	MT
18/02/21	Titan Pharmaceuticals : Maxim Group Upgrades Titan Pharmaceuticals to Buy From Hold, $11 Price Target	MT

More recommendations

Press Releases: Titan Pharmaceuticals

15/08/25	Titan Pharmaceuticals: Q2 Earnings Snapshot	AQ
06/08/25	TITAN PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Titan Pharmaceuticals, Inc. - TTNP	BU
27/06/25	Titan Pharmaceuticals Announces $600,000 Private Placement of Convertible Preferred Stock	AQ
03/06/25	Titan Pharmaceuticals Announces Filing of Registration Statement for Proposed Business Combination with TalenTec Sdn. Bhd.	AQ
15/05/25	Titan Pharmaceuticals: Q1 Earnings Snapshot	AQ

More press releases

Titan Pharmaceuticals, Inc. is a pharmaceutical company. The Company is focused on developing therapeutics utilizing the proprietary long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases. ProNeura offers continuous drug delivery and consists of a small, semi-rigid, flexible implant made from a mixture of ethylene-vinyl acetate (EVA) and a drug substance. The resulting product is a solid matrix implant that is placed subdermally, normally in the inside part of the upper arm, in a brief procedure using a local anesthetic and is removed in a similar manner at the end of the treatment period. Its product pipeline includes Kappa Opioid Receptor Agonist (TP-2021) Implant, which is used for the treatment of moderate-to-severe chronic pruritus. Its product development programs are in non-clinical stages of development.

Employees

Sector

More about the company

Quotes

Date	Price	Change	Volume
29/09/26	$0.4630	+6.73%	1,389,436
28/09/26	$0.4338	-12.91%	617,687
25/09/26	$0.4981	-7.98%	830,172
24/09/26	$0.5413	-1.40%	910,849
23/09/26	$0.5490	-2.97%	1,740,033

Delayed Quote Nasdaq

More quotes

1 year	0.41	4.8
3 years	0	14.8
5 years	0	40.6
10 years	0	21,996.03

	2023	2024
Net sales	184K 162K 153K 139K 261K 17.66M 263K 1.84M 708K 9.02M 691K 676K 28.95M	-
Net income	-5.57M -4.91M -4.65M -4.21M -7.9M -534M -7.97M -55.55M -21.43M -273M -20.91M -20.45M -876M	-4.71M -4.15M -3.93M -3.56M -6.68M -452M -6.74M -46.94M -18.1M -231M -17.67M -17.28M -740M
Net Debt	-6.2M -5.46M -5.17M -4.68M -8.79M -595M -8.87M -61.79M -23.83M -304M -23.26M -22.75M -975M	-2.83M -2.5M -2.36M -2.14M -4.02M -272M -4.05M -28.24M -10.89M -139M -10.63M -10.4M -445M

Titan Pharmaceuticals Stock

Stocks

TTNP

US8883147055

Valuation: Titan Pharmaceuticals

Chart: Titan Pharmaceuticals

Latest news: Titan Pharmaceuticals

Analysts' recommendations: Titan Pharmaceuticals

Press Releases: Titan Pharmaceuticals

Quotes and Performance

Price Extremes

Financials

Company Profile

Quotes

1 day	+6.73%
Current month	-89.96%
Current year	-89.96%